ELECTRONIC SUPPORTING INFORMATION

Studies Towards the Synthesis of Halomon: Asymmetric Hexafunctionalisation of Myrcene

D. Christopher Braddock,* Alison X. Gao, Andrew J. P. White and Mariko Whyte

Department of Chemistry, Imperial College London, South Kensington, London, SW7 2AZ, UK. Email Address: <u>c.braddock@imperial.ac.uk</u>

Cover Page and Contents

- pS1 Cover page and contents;
- pS2 General experimental;
- pS3-7 Experimental details and characterising data for compounds 6-7, 9-10, 12/13 mix, (3R,6R,7R)-3 and (3R,6S,7S)-3;
- pS8-15 Copies of ¹H and ¹³C spectra for compounds 6-7, 9-10, 12/13 mix, (3R,6R,7R)-3 and (3R,6S,7S)-3;
- pS16 X-ray crystallographic details for **6** and (3*R*,6*S*,7*S*)-**3**;

pS17 ESI References.

General Experimental.

Solvents and reagents: All reagents were obtained from commercial sources and used as received. All solvents were used as received. MeOH, CH₂Cl₂ and n-hexane were HiPerSolv grade. EtOAc was GPR grade. Petroleum ether refers to BDH AnalR petroleum spirit 40-60 °C.

Experimental techniques: Reactions were carried out under nitrogen in oven-dried glassware. The phrase "solvent removed under reduced pressure" refers to rotary evaporation. Brine refers to a saturated aqueous solution of NaCl. Column chromatography was carried out on BDH silica gel 60, grade 40-63 μ m using flash techniques. Eluents are given in parentheses. Analytical thin layer chromatography (TLC) was performed using Kieselgel 60 F₂₅₄ pre-coated aluminium-backed plates. These were visualised using ultraviolet light (254 nm) and chemical staining using potassium permanganate or vanillin solution.

Characterisation: Melting points were obtained using a Stuart SMP30 melting point apparatus and are uncorrected. Infrared (IR) spectra were obtained using a PerkinElmer Spectrum100 FTIR apparatus with automatic background subtraction and carried out neat. Proton nuclear magnetic resonance spectra (¹H NMR) were recorded at 400 MHz on Bruker DRX-400 spectrometers. Chemical shifts are referenced to the residual solvent peak, 7.26 ppm for CDCl₃ and 3.31 ppm for CD₃OD respectively. Coupling constants (*J*) are given in Hertz (Hz). Carbon nuclear magnetic resonance spectra (¹C NMR) were recorded at 100 MHz on a Bruker DRX-400 spectrometer. Chemical shifts are referenced to 77.0 ppm for CDCl₃ and 49.0 ppm for CD₃OD respectively. The following abbreviations are used for the multiplicity of NMR signals: br = broad, s = singlet, d = doublet, t = triplet, m = multiplet. Low and high resolution mass spectra were recorded by Imperial College Mass Spectrometery Service using a Micromass Platform II and Thermo Scientific Q-Exactive spectrometer. Optical Rotation measurements were made using a Bellingham+Stanley ADP410 polarimeter.

(2*S**,3*S**)-1,4-Dibromo-2-methyl-butane-2,3-diol (6) and (2*S**,3*R**)-1,4-dibromo-2-methylbutane-2,3-diol

According to a modified procedure of Sharpless² to a solution of citric

acid (3.84 g, 11.6 mmol, 2 equiv.) in t-BuOH/H₂O (20 mL of a 1:1

Br 🔪	Br _
, OH	ОН
6 L Br	Br
<i>svn</i> -diol	anti-diol

mixture) was added the allyl bromide 5 (1.33 g, 5.8 mmol) at room temperature. K₂OsO₂(OH)₄ (44.2 mg, 0.12 mmol, 2 mol%) and Nmethylmorpholine-N-oxide (747 mg, 6.38 mmol, 1.1 equiv.) were then added and the solution turned bright green. The mixture was stirred at ambient temperature for 16 h, after which time it went nearly colourless. The solution was extracted with EtOAc (3 \times 20 mL) and the combined organics were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (80:20 - 60:40 petroleum ether : EtOAc) to give the title compound 6 (1.16 g, 77%) as a white solid, and anti-diol (70 mg, 5%) as a colourless oil. Syn-6: m.p. 155 - 157°C; R_f 0.46 (60:40 petroleum ether : EtOAc); IR (neat) v_{max} 3400 (br), 2932, 1229, 1203, 1163, 1071, 676, 606, 580, 556 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.03 (dd, J = 10.4, 2.4Hz, 1H), 3.68 (dd, J = 10.4, 2.4 Hz, 1H), 3.61 (d, J = 10.2 Hz, 1H), 3.49 (t, J = 10.3 Hz, 1H), 3.44 (d, J = 10.1 Hz, 1H), 2.68 (br. s, 1H), 2.53 (br. s, 1H), 1.34 (s, 3H) ppm; ¹³C NMR (100 MHz; CDCl₃) δ 76.0, 73.5, 40.0, 36.0, 22.0 ppm; MS (CI⁺, NH₃) m/z 282, 280, 278 [M + NH₄]⁺; HRMS (CI^{+}, NH_{3}) calcd for $C_{5}H_{14}^{79}Br_{2}NO_{2}$ 277.9391 $[M + NH_{4}]^{+}$, found 277.9378. The syn-diol 6 was recrystallised from a mixture of n-hexane and CH₂Cl₂ to give a crystals suitable for X-ray crystallography. Crystal data for 6: $C_5H_{10}Br_2O_2$, M = 261.95, monoclinic, $P2_1/n$ (no. 14), a =2.124 g cm⁻³, μ (Cu-K α) = 12.043 mm⁻¹, T = 173 K, colourless blocky needles, Oxford Diffraction Xcalibur PX Ultra diffractometer; 1597 independent measured reflections ($R_{int} = 0.0231$), F^2 refinement, $R_1(obs) = 0.0223$, $wR_2(all) = 0.0519$, 1440 independent observed absorption-corrected reflections $[|F_o| > 4\sigma(|F_o|), 2\theta_{max} = 144^\circ], 91$ parameters. CCDC 1017807. Anti-6: R_f 0.48 (60:40 petroleum ether : EtOAc); IR (neat) v_{max} 3300 (br), 2936, 1245, 1225, 1065, 647, 575 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 3.97 (ddd, J = 10.3, 3.7, 2.1 Hz, 1H), 3.85 (dd, J = 10.3, 2.0 Hz, 1H), 3.81 (d, J = 10.7 Hz, 1H), 3.55 (d, J = 10.3 Hz, 1H), 3.46 (t, J = 10.3 Hz, 1H), 2.61 (d, J = 3.5 Hz, 1H), 2.37 (s, 1H), 1.34 (s, 3H) ppm; ¹³C NMR (100 MHz; CDCl₃) & 75.3, 73.0, 43.2, 36.6, 19.9 ppm; MS (CI⁺, NH₃) m/z 282, 280, 278 [M + NH₄]⁺; HRMS (CI⁺, NH₃) calcd for C₅H₁₄⁷⁹Br₂NO₂ $277.9391 [M + NH_4]^+$, found 277.9378.

(3R)-2-Methyl-6-methylene-oct-7-ene-2,3-diol (7)

HO HO OH_7 According to method of Sharpless,⁴ to a stirred solution of AD-mix- β (10.2 g) in 1:1 v/v *t*-BuOH/H₂O (72 mL) at ambient temperature was added methanesulfonamide (1.47 g, 15.5 mmol, 1.03 equiv.). The reaction mixture

was stirred vigorously at this temperature for 0.5 h until the mixture became a homogeneous orange solution and myrcene (**2**) (685 mg, 2.8 mL, 15.0 mmol) was added in one portion. The reaction mixture was stirred at room temperature for 20 h. The reaction was quenched with Na₂SO₃ (20 g) and stirred for 1 h at ambient temperature. Water (20 mL) was added and two phases were separated. The aqueous phase was extracted with EtOAc (5×20 mL). The combined organic phases were washed with brine (100 mL), dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. The residue was chromatographed (80:20 – 60:40 petroleum ether : EtOAc) to give (*R*)-diol 7 (1.70 g, 67%) as a colourless oil: R_f 0.46 (50:50 petroleum ether : EtOAc); $[\alpha]_D^{25}$ + 34.0 (*c* = 1.0, CHCl₃) {lit.⁵ $[\alpha]_D^{22}$ + 37.4 (*c* = 1.0, CHCl₃)} 91% ee; IR (neat) v_{max} 3377 (br), 2972, 2934, 2876, 1722, 1245, 1155, 1048, 939 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 6.38 (dd, *J* = 17.6, 10.8 Hz, 1H), 5.27 (d, *J* = 17.6 Hz, 1H), 5.08 (d, *J* = 10.8 Hz, 1H), 5.06 – 5.02 (m, 3H), 3.41 (dd, *J* = 10.4, 1.9 Hz, 1H), 2.59 – 2.47 (m, 1H), 2.34 – 2.21 (m, 1H), 2.15-1.80 (br s, 2H), 1.74 – 1.62 (m, 1H), 1.57 – 1.44 (m, 1H), 1.21 (s, 3H), 1.16 (s, 3H) ppm; ¹³C NMR (100 MHz; CDCl₃) δ 146.1, 138.7, 116.1, 113.6, 78.2, 73.1, 30.2, 28.5, 26.5, 23.2 ppm; MS (CI⁺, NH₃) *m/z* 188 [M + NH₄]⁺; HRMS (CI⁺, NH₃) calcd for C₁₀H₂₂NO₂ [M + NH₄]⁺ 188.1651, found 188.1651.

(3R)-4,4-Dimethyl-5-(3-methylene-pent-4-enyl)-2-phenyl-[1,3,2]dioxaborolane (9)

Using a modified method of Muñiz⁶ to a solution of containing AD-mix- β (10.2 g), phenylboronic acid (2.19 g, 18 mmol, 1.2 equiv.) in *t*-BuOH/H₂O (50 mL of a 1:1 mixture) was added additional K₂OsO₂(OH)₄ (55.3 mg, 0.15 mmol, 1 mol%), (DHQD)₂PHAL (233.7 mg, 0.3 mmol, 2 mol%). The mixture was stirred vigorously at room temperature until all materials had dissolved. Myrcene (2) (685 mg, 2.8 mL, 15 mmol) was added in one portion and the mixture was stirred at ambient temperature for 20 h and then quenched with sat. aq. Na₂S₂O₃ solution (50 mL). Two phases were separated and the aqueous phase was extracted with diethyl ether (5 × 20 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. Purification by column chromatography (90:10 petroleum ether : EtOAc); $[\alpha]_D^{25} + 34.0$ (*c* = 1.0, CHCl₃); IR (neat) *v*_{max} 3088, 2976, 1600, 1500, 1270, 1228, 1143, 1097, 1068, 1027 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.84 (dd, *J* = 8.0, 1000 method set for the set of the 1.3 Hz, 2H), 7.51 – 7.43 (m, 1H), 7.42 – 7.35 (m, 2H), 6.42 (dd, J = 17.6, 10.8 Hz, 1H), 5.33 (d, J = 17.6 Hz, 1H), 5.16 – 5.06 (m, 3H), 4.13 (dd, J = 10.6, 3.0 Hz, 1H), 2.67 (ddd, J = 14.7, 10.2, 4.6 Hz, 1H), 2.43 – 2.31 (m, 1H), 1.87 – 1.75 (m, 1H), 1.73 – 1.63 (m, 1H), 1.45 (s, 3H), 1.30 (s, 3H); ¹³C NMR (100 MHz; CDCl₃) δ 145.8, 138.7, 134.8, 131.3, 127.8, 116.3, 113.6, 85.3, 82.1, 30.4, 28.8, 28.3, 23.5 ppm; MS (CI⁺, NH₃) m/z 274, 273 [M + NH₄]⁺; HRMS (CI⁺, NH₃) calcd for C₁₆H₂₅¹¹BNO₂ 274.1978 [M + NH₄]⁺, found 274.1986.

Deprotection of boronate 9 to diol 7

According to the procedure reported by Sharpless,⁷ to a stirred solution of the boronic ester **9** (100 mg, 0.39 mmol) in EtOAc:acetone (6 mL of a 1:1 mixture) at room temperature was added a 30% aqueous solution of hydrogen peroxide (0.11 g, 0.98 mmol, 2.5 equiv.) in one portion. The reaction mixture was stirred at room temperature for 4 h and water (10 mL) was added. The layers were separated and the aqueous layer was extracted with EtOAc (4 × 20 mL), and the combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. The residue was purified by column chromatography (40:60 petroleum ether : EtOAc) to give the title compound **7** (60 mg, 90%) as a colourless oil. R_f 0.40 (50:50 petroleum ether : EtOAc); $[\alpha]_D^{25} + 34.0$ (c = 1.0, CHCl₃) {lit.⁵ $[\alpha]_D^{22} + 37.4$ (c = 1.0, CHCl₃)} 91% ee. All other data identical to that reported above for diol 7.

(3*R*)-5-(5-Bromo-3-bromomethyl-pent-3-enyl)-4,4-dimethyl-2-phenyl-[1,3,2]dioxaborolane (10)

According to a modified procedure of Alexakis,¹ to a stirred suspension of Br diene 9 (260 mg, 1.02 mmol) and K₂CO₃ (14 mg, 0.1 mmol, 0.1 equiv.) in B-Ō 10 hexane (30 mL) at -78 °C was added a solution of molecular Br₂ (0.06 mL, Br Ph 1.02 mmol) in hexane (10 mL), dropwise, in the absence of light and the mixture was stirred for 2 h. The reaction mixture was quenched with Na_2SO_3 (5 g) and then allowed to warm to ambient temperature. Water (30 mL) was added and two phases were separated. The aqueous phase was extracted with ether (3 \times 20 mL). The combined organic extracts were dried over MgSO₄ and concentrated in vacuo to provide the title compound 10 (420 mg, 100%) as a pale vellow oil, which was taken on further without purification. $R_f = 0.20$ (90:10 petroleum ether : EtOAc); $[\alpha]_D^{25} + 26.0$ (*c* = 1.0, CHCl₃); IR (neat) *v*_{max} 3085, 3055, 2973, 2935, 2881, 1603, 1350, 1270, 1203, 1146, 1096, 1068, 1026, 669, 650, 559 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.89 – 7.76 (d, J = 6.8 Hz, 2H), 7.48 (t, J = 7.3 Hz), 7.39 (dd, J = 7.9, 6.8 Hz, 2H), 5.99 (t, J = 8.4 Hz, 1H), 4.11 – 4.03 (m, 5H),

2.69 – 2.63 (m, 1H), 2.58 – 2.49 (m, 1H), 1.79 – 1.69 (m, 2H), 1.45 (s, 3H), 1.29 (s, 3H) ppm; ¹³C NMR (100 MHz; CDCl₃) δ 140.8, 134.8, 131.4, 127.8, 127.7, 84.6, 82.0, 37.1, 29.8, 28.8, 27.2, 25.5, 23.5 ppm; MS (CI⁺, NH₃) *m/z* 436, 435, 434, 343, 432, 431 [M + NH₄]⁺; HRMS (CI⁺, NH₃) calcd for C₁₆H₂₅¹¹B⁷⁹Br₂NO₂ 432.0345 [M + NH₄]⁺, found 432.0344.

(3R,6S,7S)- and (3R,6R,7R)-5-[2-(4,5-*Bis*-bromomethyl-2-phenyl-[1,3,2]dioxaborolan-4-yl)ethyl]-4,4-dimethyl-2-phenyl-[1,3,2]dioxaborolane (12 and 13)



According to a modified method of Sharpless,² to a solution of the citric acid (420 mg, 2 mmol, 2 equiv.) in *t*-BuOH/H₂O (10 mL of a 1:1 mixture) was added allyl bromide **10** (416 mg, 1 mmol) at

room temperature. K₂OsO₂(OH)₄ (29.5 mg, 0.08 mmol, 4 mol%), N-methylmorpholine-N-oxide (128.9 mg, 1.1 mmol, 1.1 equiv.) and phenylboronic acid (121.9 mg, 1 mmol, 1 equiv.) were then added and the solution turned bright green. The mixture was stirred at ambient temperature for 16 h, after which time it went nearly colourless. The solution was extracted with EtOAc (3×20 mL) and the combined organics were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was chromatographed (80:20 petroleum ether : EtOAc) to give a ca. 1:1 inseparable diastereomeric mixture of the title compounds 12 and 13 (450 mg, 85%) as a brown oil which could be used directly in the next step. Further chromatography gave the boronate mixture as a yellow oil: $R_f 0.38$ (90:10 petroleum ether : EtOAc); IR (neat) v_{max} 3059, 2935, 1348, 1295, 1267, 1223, 1152, 1026, 669, 646, 620, 537 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.88 – 7.76 (m, 8H), 7.55 - 7.31 (m, 12H), 4.84 - 4.78 (m, 2H), 4.10 (dd, J = 5.7, 4.0 Hz, 2H), 3.75 - 3.54 (m, 8H), 2.42(ddd, J = 13.9, 11.7, 4.9 Hz, 1H), 2.36 - 2.25 (m, 1H), 1.99 - 1.81 (m, 4H), 1.80 - 1.62 (m, 2H),1.47 (s, 3H), 1.45 (s, 3H), 1.35 (s, 3H), 1.32 (s, 3H,) ppm; ¹³C NMR (100 MHz; CDCl₃) δ 135.1, 134.8, 132.0, 132.0, 131.4, 131.0, 128.8, 128.0, 127.9, 127.9, 127.8, 85.7, 85.4, 84.4, 84.2, 83.0, 82.7, 82.1, 82.1, 38.1, 37.6, 31.7, 31.2, 29.4, 29.2, 29.0, 28.9, 25.6, 23.6, 23.5, 21.1 ppm; MS (EI⁺) m/z 538, 537, 536, 535, 534, 533, 532 [M]⁺⁺; HRMS (EI⁺) calcd for C₂₂H₂₆⁻¹¹B₂⁻⁷⁹Br₂O₄ 534.0384 [M]^{+•}, found 534.0397.

(3*R*,6*R*,7*R*)- and (3*R*,6*S*,7*S*)-2-Methyl-6-bromomethyl-8-bromooctane-2,3,6,7-tetrols [(3*R*,6*R*,7*R*)-3 and (3*R*,6*S*,7*S*)-3]



Adapting a method described by Padwa,⁸ to a solution of the mixture of diboronates **12** and **13** (158 mg, 0.3 mmol) and AcOH (10 μ L, 0.2 mmol, 0.6 eq.) in CH₂Cl₂ (5 mL) was added

pinacol (248 mg, 2.1 mmol, 7.0 eq.) and the reaction was stirred at ambient temperature for 72h. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography (50:50 - 10:90, petroleum ether: EtOAc) to give the two diastereomeric products as off-white crystalline solids (90 mg, 0.25 mmol, 82%) as a *ca*. 1:1 mixture. Analytically pure samples of each could be obtained by further careful chromatography. (3R, 6R, 7R)-3: crystalline white solid, m.p. 102-105 °C; $R_f = 0.49$ (10:90, pet. ether : EtOAc); $[\alpha]_D^{25} + 21.8$ (c = 0.3, MeOH);⁹ IR (neat) v_{max} 3379 (br), 2974, 2937, 1433, 1386, 1230, 1159, 1159, 1071 cm⁻¹; ¹H NMR (400 MHz, MeOD) δ 3.94 (dd, J = 10.0, 2.0 Hz, 1H), 3.82 (dd, J = 10.4, 2.0 Hz, 1H), 3.66 (d, J = 10.4Hz, 1H), 3.54 (d, J = 10.4 Hz, 1H), 3.43 (t, J = 10.4 Hz, 1H), 3.26 (dd, J = 10.0, 2.0 Hz, 1H), 2.04-1.94 (m, 1H), 1.79-1.65 (m, 2H), 1.40-1.31 (m, 1H), 1.20 (s, 3H), 1.18 (s, 3H) ppm; ¹³C NMR (100 MHz, CD₃OD) δ 78.6, 75.1, 74.4, 72.4, 37.0 35.0, 32.3, 24.3, 24.1, 23.7 ppm; HRMS (TOF, ES⁻) m/z calcd for C₁₀H₁₉⁷⁹Br₂O₄ (M-H)⁻ 360.9650, found 360.9623. (3*R*,6*S*,7*S*)-**3**: crystalline white solid, m.p. 135-137 °C; $R_f = 0.46$ (10:90, pet. ether : EtOAc); $[\alpha]_D^{25} + 9.2$ (c = 0.2, MeOH); ⁹ IR (neat) v_{max} 3366 (br), 2974, 1632, 1389, 1431, 1227, 1161, 1077, 971 cm⁻¹; ¹H NMR (400 MHz, CD₃OD) δ 3.95 (dd, J = 10.0, 2.0 Hz, 1H), 3.80 (dd, J = 10.8, 2.0 Hz, 1H), 3.69 (d, J = 10.4 Hz, 1H), 3.49 (d, J = 10.4 Hz, 1H), 3.44 (t, J = 10.4 Hz, 1H), 3.26 (dd, J = 10.0, 2.0 Hz, 1H), 2.01-1.93(m, 1H), 1.77-1.68 (m, 2H), 1.48-1.39 (m, 1H), 1.20 (s, 3H), 1.18 (s, 3H) ppm; ¹³C NMR (100 MHz, MeOD) δ 78.5, 75.1, 74.3, 72.4, 36.4, 34.8, 32.1, 24.3, 24.0, 23.6 ppm; HRMS (TOF, ES⁻) m/z calcd for C₁₀H₁₉⁷⁹Br₂O₄ (M-H)⁻ 360.9650, found 360.9654; Crystal data for (3*R*,6*S*,7*S*)-3: $C_{10}H_{20}Br_2O_4$, M = 364.08, orthorhombic, $P2_12_12_1$ (no. 19), a = 5.2172(3), b = 12.8186(6), c = 12.8186(6)21.7125(15) Å, V = 1452.07(15) Å³, Z = 4, $D_c = 1.665$ g cm⁻³, μ (Mo-K α) = 5.580 mm⁻¹, T = 173 K, colourless platy needles, Agilent Xcalibur 3E diffractometer; 2874 independent measured reflections ($R_{int} = 0.0264$), F^2 refinement, $R_1(obs) = 0.0543$, $wR_2(all) = 0.0830$, 2040 independent observed absorption-corrected reflections $[|F_0| > 4\sigma(|F_0|), 2\theta_{max} = 56^\circ]$, 163 parameters. The absolute structure of (3R, 6S, 7S)-3 was determined by use of the Flack parameter [x = 0.014(12)]. CCDC 1017806.

¹H NMR spectrum (400 MHz, CDCl₃) of $(2S^*, 3S^*)$ -1,4-dibromo-2-methyl-butane-2,3-diol (6)



 13 C NMR spectrum (100 MHz, CDCl₃) of (2*S**,3*S**)-1,4-dibromo-2-methyl-butane-2,3-diol (6)





¹H NMR spectrum (400 MHz, CDCl₃) of (2*S**,3*R**)-1,4-dibromo-2-methyl-butane-2,3-diol

¹³C NMR spectrum (100 MHz, CDCl₃) of (2*S**,3*R**)-1,4-dibromo-2-methyl-butane-2,3-diol



¹H NMR spectrum (400 MHz, CDCl₃) of (3*R*)-2-methyl-6-methylene-oct-7-ene-2,3-diol (7)



¹³C NMR spectrum (100 MHz, CDCl₃) of (3*R*)-2-methyl-6-methylene-oct-7-ene-2,3-diol (7)



¹H NMR spectrum (400 MHz, CDCl₃) of (3R)-4,4-dimethyl-5-(3-methylene-pent-4-enyl)-2-phenyl-[1,3,2]dioxaborolane (9)



¹³C NMR spectrum (100 MHz, CDCl₃) of (3*R*)-4,4-dimethyl-5-(3-methylene-pent-4-enyl)-2phenyl-[1,3,2]dioxaborolane (**9**)



¹H NMR spectrum (400 MHz, CDCl₃) of (3*R*)-5-(5-bromo-3-bromomethyl-pent-3-enyl)-4,4dimethyl-2-phenyl-[1,3,2]dioxaborolane (**10**)



¹³C NMR spectrum (100 MHz, CDCl₃) of (3*R*)-5-(5-bromo-3-bromomethyl-pent-3-enyl)-4,4dimethyl-2-phenyl-[1,3,2]dioxaborolane (10)



¹H NMR spectrum (top) (400 MHz, CDCl₃) and ¹³C NMR spectrum (bottom) (100 MHz, CDCl₃) of a *ca*. 1:1 mixture of (3*R*,6*S*,7*S*)- and (3*R*,6*R*,7*R*)-5-[2-(4,5-*bis*-bromomethyl-2-phenyl-[1,3,2]dioxaborolan-4-yl)-ethyl]-4,4-dimethyl-2-phenyl-[1,3,2]dioxaborolanes (12 and 13)



¹H NMR spectrum (400 MHz, CD₃OD) of (3R, 6R, 7R)-2-methyl-6-bromomethyl-8-bromooctane-2,3,6,7-tetrol [(3R, 6R, 7R)-3]



¹³C NMR spectrum (100 MHz, CD₃OD) of (3*R*,6*R*,7*R*)-2-methyl-6-bromomethyl-8-bromooctane-





¹H NMR spectrum (400 MHz, CD₃OD) of (3R,6S,7S)-2-methyl-6-bromomethyl-8-bromooctane-2,3,6,7-tetrol [(3R,6S,7S)-3]



¹³C NMR spectrum (100 MHz, CD₃OD) of (3*R*,6*S*,7*S*)-2-methyl-6-bromomethyl-8-bromooctane-2,3,6,7-tetrol [(3*R*,6*S*,7*S*)-**3**]



X-Ray Crystallography

The X-ray crystal structure of 6

The two O–H hydrogen atoms in the structure of **6** were both located from ΔF maps and refined freely subject to O–H distance constraints of 0.90 Å.



Fig. S1 The crystal structure of 6 (50% probability ellipsoids).

The X-ray crystal structure of (3R,6S,7S)-3

The four O–H hydrogen atoms in the structure of (3R,6S,7S)-**3** were all located from ΔF maps and refined freely subject to O–H distance constraints of 0.90 Å. The absolute structure of (3R,6S,7S)-**3** was determined by use of the Flack parameter [x = 0.014(12)].



Fig. S2 The crystal structure of (3*R*,6*S*,7*S*)-**3** (50% probability ellipsoids).

References:

- 1. Falciola, C. A.; Tissot-Crosset, K.; Reyneri, H.; Alexakis, A. Adv. Synth. Catal. 2008, 350, 1090-1100.
- 2. Dupau, P.; Epple, R.; Thomas, A. A; Fokin, V. V.; Sharpless, K. B. Adv. Synth. Catal. 2002, 344, 421-433.
- 3. SHELXTL, Bruker AXS, Madison, WI; SHELX-97, G.M. Sheldrick, *Acta Cryst.*, **2008**, *A64*, 112-122; SHELX-2013, <u>http://shelx.uni-ac.gwdg.de/SHELX/index.php</u>
- Sharpless, K. B.; Amberg, W.; Bennani, Y. L.; Crispino, G. A.; Hartung, J.; Jeong, K.-S.; Kwong, H.-L.; Morikawa,
 K.; Wang, Z.-M.; Xu, D.; Zhang, X.-L. J. Org. Chem. 1992, 57, 2768-2271.
- 5. Hioki, H.; Ooi, H.; Hamano, M.; Mimura, Y.; Yoshio, S.; Kodama, M.; Ohta, S.; Yanai, M.; Ikegami, S. *Tetrahedron* **2001**, *57*, 1235-1246.
- 6. Hövelmann, C. H.; Muñiz, K. Chem. Eur. J. 2005, 11, 3951-3958.
- 7. Gypser, A.; Michel, D. Nirschl, D. S.; Sharpless, K. B. J. Org. Chem. 1998, 63, 7322-7327.
- 8. Padwa, A.; Wang, Q. J. Org. Chem. 2006, 71, 7391-7402.
- 9. Optical rotations recorded by Mr James Clarke, Department of Chemistry, Imperial College London.